SCHEMBL12929697

SCHEMBL12929697

CCOC(=O)c1cnc(-c2ccncc2)nc1NCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 1/20 0.61
▸ DBF4 Q9UBU7 1/20 0.61
▸ NPSR1 Q6W5P4 4/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ CYP1A2 P05177 2/20 0.59
▸ CYP2C9 P11712 2/20 0.59
▸ CYP2C19 P33261 2/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ GAA P10253 1/20 0.59
▸ ALDH1A1 P00352 7/20 0.58
▸ MAPT P10636 6/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.58
▸ LMNA P02545 3/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ TP53 P04637 2/20 0.58
▸ FOS P01100 2/20 0.58
▸ JUN P05412 2/20 0.58
▸ NFKB1 P19838 2/20 0.58
▸ NFKB2 Q00653 2/20 0.58
▸ RELA Q04206 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11164512 0.93 NPSR1 (0.67) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL12929526 0.90 NPSR1 (0.57) CDC7DBF4NPSR1RAB9ACYP1A2
SCHEMBL11159729 0.85 ALDH1A1 (0.66) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL12929645 0.84 NPSR1 (0.60) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL12929641 0.83 FOS (0.66) CDC7DBF4RAB9ACYP1A2CYP2C9
SCHEMBL11158474 0.83 ALDH1A1 (0.69) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL12929351 0.83 ALDH1A1 (0.64) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL12929381 0.82 NPSR1 (0.58) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL12929613 0.81 NPSR1 (0.57) NPSR1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL12929397 0.81 ADORA3 (0.67) NPSR1RAB9ACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS KCNJ1, KCNJ11, TRPV1 CDC7 2347/4885DBF4 1992/4885NPSR1 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback